Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.

Henry Ginsberg, Bertrand Cariou, Trevor Orchard, Lei Chen, Junxiang Luo, Edward J Bastyr, Juliana Bue-Valleskey, Annette M Chang, Tibor Ivanyi, Scott J Jacober, Byron J Hoogwerf

Diabetes, obesity & metabolism 2016 Nov

filter terms:

Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH) from phase III studies in type 1 diabetes (T1D), insulin-naïve patients with type 2 diabetes (T2D), patients with T2D on basal insulin only and patients with T2D on basal-bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides (TG) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin-naïve patients with T2D, TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH. The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion. © 2016 John Wiley & Sons Ltd.

Citation

Henry Ginsberg, Bertrand Cariou, Trevor Orchard, Lei Chen, Junxiang Luo, Edward J Bastyr, Juliana Bue-Valleskey, Annette M Chang, Tibor Ivanyi, Scott J Jacober, Byron J Hoogwerf. Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials. Diabetes, obesity & metabolism. 2016 Nov;18(11):1089-1092